United States - English - NLM (National Library of Medicine)

liberty pharmaceuticals, inc. - doxycycline hyclate (unii: 19xts3t51u) (doxycycline anhydrous - unii:334895s862) - doxycycline anhydrous 100 mg - to reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline hyclate capsules, usp and other antibacterial drugs, doxycycline hyclate capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. doxycycline is indicated for the treatment of the following infections: - rocky mountain spotted fever, typhus fever and the typhus group, q fever, rickettsialpox, and tick fevers caused by rickettsiae. - respiratory tract infections caused by mycoplasma pneumoniae . - lymphogranuloma venereum caused by chlamydia trachomatis . - psittacosis (omithosis) caused by chlamydia trachomatis . - trachoma caused by chlamydia trachomatis , although the infectious

United States - English - NLM (National Library of Medicine)

liberty pharmaceuticals, inc. - dicloxacillin sodium (unii: 4hzt2v9kx0) (dicloxacillin - unii:cof19h7wbk) - dicloxacillin 250 mg - the penicillinase-resistant penicillins are indicated in the treatment of infections caused by penicillinase-producing staphylococci which have demonstrated susceptibility to the drugs. cultures and susceptibility tests should be performed initially to determine the causative organism and their sensitivity to the drug (see clinical pharmacology – susceptibility testing ). the penicillinase-resistant penicillins may be used to initiate therapy in suspected cases of resistant staphylococcal infections prior to the availability of laboratory test results. the penicillinase-resistant penicillins should not be used in infections caused by organisms susceptible to penicillin g. if the susceptibility tests indicate that the infection is due to an organism other than a resistant staphylococcus, therapy should not be continued with a penicillinase-resistant penicillin. to reduce the development of drug-resistant bacteria and maintain the effectiveness of dicloxacillin sodium capsules and other antibacterial drugs, dic

United States - English - NLM (National Library of Medicine)

liberty pharmaceuticals, inc. - atropine sulfate (unii: 03j5ze7ka5) (atropine - unii:7c0697dr9i), hyoscyamine sulfate (unii: f2r8v82b84) (hyoscyamine - unii:px44xo846x), scopolamine hydrobromide (unii: 451ifr0gxb) (scopolamine - unii:dl48g20x8x), phenobarbital (unii: yqe403bp4d) (phenobarbital - unii:yqe403bp4d) - glaucoma, obstructive uropathy (for example, bladder neck obstruction due to prostatic hypertrophy); obstructive disease of the gastrointestinal tract (as in achalasia, pyloroduodenal stenosis, etc.); paralytic ileus, intestinal atony of the elderly or debilitated patient; unstable cardiovascular status in acute hemorrhage; severe ulcerative colitis especially if complicated by toxic magacolon; myasthenia gravis; hiatal hernia associated with reflux esophagitis. belladonna alkaloids with phenobarbital tablets are contraindicated in patients with known hypersensitivity to any of the ingredients. phenobarbital is contraindicated in acute intermittent porphyria and in those patients in whom phenobarbital produces restlessness and/or excitement.

United States - English - NLM (National Library of Medicine)

liberty pharmaceuticals, inc. - phenazopyridine hydrochloride (unii: 0ewg668w17) (phenazopyridine - unii:k2j09emj52) - phenazopyridine hydrochloride 100 mg - phenazopyridine hcl is indicated for the symptomatic relief of pain, burning, urgency, frequency, and other discomforts arising from irritation of the lower urinary tract mucosa caused by infection, trauma, surgery, endoscopic procedures, or the passage of sounds or catheters. the use of phenazopyridine hcl for relief of symptoms should not delay definitive diagnosis and treatment of causative conditions. because it provides only symptomatic relief, prompt appropriate treatment of the cause of pain must be instituted and phenazopyridine hcl should be discontinued when symptoms are controlled. the analgesic action may reduce or eliminate the need for systemic analgesics or narcotics. it is, however, compatible with antibacterial therapy and can help to relieve pain and discomfort during the interval before antibacterial therapy controls the infection. treatment of a urinary tract infection with phenazopyridine hcl should not exceed 2 days because there is a lack of evidence that the combined administration of

United States - English - NLM (National Library of Medicine)

liberty pharmaceuticals, inc. - benzonatate (unii: 5p4dhs6enr) (benzonatate - unii:5p4dhs6enr) - benzonatate 100 mg - benzonatate usp is indicated for the symptomatic relief of cough. hypersensitivity to benzonatate or related compounds. pediatric use safety and effectiveness in children below the age of 10 have not been established. accidental ingestion resulting in death has been reported in children below age 10. keep out of reach of children.

United States - English - NLM (National Library of Medicine)

liberty pharmaceuticals, inc. - nitrofurantoin (unii: 927ah8112l) (nitrofurantoin - unii:927ah8112l) - nitrofurantoin 100 mg - nitrofurantoin macrocrystals is specifically indicated for the treatment of urinary tract infections when due to susceptible strains of escherichia coli , enterococci, staphylococcus aureus , and certain susceptible strains of klebsiella and enterobacter species. nitrofurantoin is not indicated for the treatment of pyelonephritis or perinephric abscesses. to reduce the development of drug-resistant bacteria and maintain the effectiveness of nitrofurantoin macrocrystals and other antibacterial drugs, nitrofurantoin macrocrystals should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. nitrofurantoins lack the broader tissue distribution of other therapeutic agents approved for urina

United States - English - NLM (National Library of Medicine)

liberty pharmaceuticals, inc. - phenazopyridine hydrochloride (unii: 0ewg668w17) (phenazopyridine - unii:k2j09emj52) - phenazopyridine hydrochloride 100 mg - phenazopyridine hcl is indicated for the symptomatic relief of pain, burning, urgency, frequency, and other discomforts arising from irritation of the lower urinary tract mucosa caused by infection, trauma, surgery, endoscopic procedures, or the passage of sounds or catheters. the use of phenazopyridine hcl for relief of symptoms should not delay definitive diagnosis and treatment of causative conditions. because it provides only symptomatic relief, prompt appropriate treatment of the cause of pain must be instituted and phenazopyridine hcl should be discontinued when symptoms are controlled. the analgesic action may reduce or eliminate the need for systemic analgesics or narcotics. it is, however, compatible with antibacterial therapy and can help to relieve pain and discomfort during the interval before antibacterial therapy controls the infection. treatment of a urinary tract infection with phenazopyridine hcl should not exceed two days because there is a lack of evidence that the combined administration o

United States - English - NLM (National Library of Medicine)

liberty pharmaceuticals, inc. - phenazopyridine hydrochloride (unii: 0ewg668w17) (phenazopyridine - unii:k2j09emj52) - urinary analgesic fast relief from urinary pain, burning, urgency and frequency associated with urinary tract infections

United States - English - NLM (National Library of Medicine)

liberty pharmaceuticals, inc. - docusate sodium (unii: f05q2t2ja0) (docusate - unii:m7p27195ag) - stool softener - relieves occasional constipation (irregularity) - generally produces bowel movement in 12 to 72 hours

United States - English - NLM (National Library of Medicine)

liberty pharmaceuticals, inc. - aspirin (unii: r16co5y76e) (aspirin - unii:r16co5y76e) - pain reliever - for the temporary relief of minor aches and pains or as recommended by your doctor. because of its delayed action, this product may not provide fast relief of headache or other symptoms needing immediate relief. - ask your doctor about other uses for this product.